HTG Molecular Diagnostics Management
Management criteria checks 2/4
HTG Molecular Diagnostics' CEO is John Lubniewski, appointed in Apr 2018, has a tenure of 6.08 years. total yearly compensation is $913.89K, comprised of 58.9% salary and 41.1% bonuses, including company stock and options. directly owns 0.053% of the company’s shares, worth $2.94. The average tenure of the management team and the board of directors is 8.1 years and 5.1 years respectively.
Key information
John Lubniewski
Chief executive officer
US$913.9k
Total compensation
| CEO salary percentage | 58.9% |
| CEO tenure | 6.1yrs |
| CEO ownership | 0.05% |
| Management average tenure | 8.1yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
HTG Molecular Q2 GAAP loss per share widens, revenue down
Aug 11HTG Molecular Diagnostics amends senior loan facility
Jul 18Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?
Dec 10
Is HTG Molecular Diagnostics (NASDAQ:HTGM) Weighed On By Its Debt Load?
Aug 27HTG Molecular completes product design lock for planned transcriptome panel
Jun 14These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat
Mar 26What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Jan 20
HTG shares surge after upbeat 2020 revenue forecast
Jan 05HTG Molecular Diagnostics announced 1:15 reverse stock split
Nov 23HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow
Nov 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$20m |
| Dec 31 2022 | US$914k | US$538k | -US$22m |
| Sep 30 2022 | n/a | n/a | -US$22m |
| Jun 30 2022 | n/a | n/a | -US$22m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$737k | US$460k | -US$17m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$17m |
| Mar 31 2021 | n/a | n/a | -US$20m |
| Dec 31 2020 | US$1m | US$416k | -US$21m |
| Sep 30 2020 | n/a | n/a | -US$21m |
| Jun 30 2020 | n/a | n/a | -US$20m |
| Mar 31 2020 | n/a | n/a | -US$19m |
| Dec 31 2019 | US$1m | US$384k | -US$19m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$1m | US$327k | -US$16m |
| Sep 30 2018 | n/a | n/a | -US$16m |
| Jun 30 2018 | n/a | n/a | -US$17m |
| Mar 31 2018 | n/a | n/a | -US$19m |
| Dec 31 2017 | US$691k | US$307k | -US$19m |
Compensation vs Market: John's total compensation ($USD913.89K) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Lubniewski (59 yo)
6.1yrs
Tenure
US$913,891
Compensation
Mr. John L. Lubniewski serves as President of HTG Molecular Diagnostics, Inc. since April 16, 2018 and also serves as its Chief Executive Officer since April 2019. Mr. Lubniewski served as Chief Operating...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.1yrs | US$913.89k | 0.053% $ 2.9 | |
| Senior VP | 12.3yrs | US$580.32k | 0.040% $ 2.2 | |
| Senior Vice President of Finance & Administration | 2.3yrs | no data | 0.018% $ 1.0 | |
| Senior VP & Chief Legal Counsel | 12.9yrs | US$296.70k | no data | |
| Senior Vice President of Research & Development | 10.1yrs | US$507.38k | no data | |
| Senior Vice President of Therapeutics | 2.6yrs | no data | 0.019% $ 1.1 | |
| Vice President of Target Strategy & Early Development | no data | no data | no data | |
| Vice President of Scientific Innovation | no data | no data | no data |
8.1yrs
Average Tenure
60yo
Average Age
Experienced Management: HTGM.Q's management team is seasoned and experienced (8.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.1yrs | US$913.89k | 0.053% $ 2.9 | |
| Independent Director | 5.8yrs | US$54.75k | 0.00059% $ 0.03 | |
| Independent Director | 8.6yrs | US$49.41k | 0.0012% $ 0.07 | |
| Independent Chairman of the Board | 7.8yrs | US$80.05k | 0.0018% $ 0.1 | |
| Independent Director | 1.8yrs | US$11.00k | no data | |
| Non-Employee Independent Director | 2.3yrs | US$53.83k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Therapeutics Scientific Advisory Board | 2.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.1yrs
Average Tenure
62yo
Average Age
Experienced Board: HTGM.Q's board of directors are considered experienced (5.1 years average tenure).